Prevalence of the Eosinophilic Phenotype Among Severe Asthma Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of this cross-sectional, multicenter study is to determine the prevalence of an eosinophilic phenotype of blood eosinophil count ≥ 300 cells/mm3 among severe asthma patients who attend to sites specialized in the management of severe asthma in several countries in the AstraZeneca International Region. The prevalence of an atopic phenotype and asthma control, will also be studied.

Detailed Description
-----------------
To determine the prevalence of an eosinophilic phenotype of blood eosinophil count ≥ 300 cells/mm3 among severe asthma patients attending their routine clinical visit at sites specialized in the management of severe asthma in several countries in the AstraZeneca International Region. The prevalence of an atopic phenotype and the status of asthma control, will also be studied. It is expected that this study will contribute to the understanding of severe asthma, ultimately helping to inform therapeutic decisions and addressing patients' needs.

Official Title
-----------------
PREPARE STUDY: PRevalence of the Eosinophilic Phenotype Among SeveRE Asthma Patients in AstraZeneca International Region. A Multinational, Cross-Sectional, Multicenter Study

Conditions
-----------------
Severe Asthma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Patients must fulfil all of the following inclusion criteria to be included in the study: Male or female patient, aged 12 years or older by the time of study entry Patient visiting a participating center for a routine clinical appointment Patient is willing and able to provide a blood sample for IgE and eosinophil levels determination as part of their routine clinical visit Diagnosis of severe asthma for at least one year as defined by: Treatment with guidelines-suggested medications for Global Initiative for Asthma (3) steps 4-5 asthma Patients or their legal guardian, who voluntarily sign and date the informed consent form prior to study entry. Exclusion Criteria Patients with a diagnosis of chronic obstructive pulmonary disease or other chronic respiratory condition beyond severe asthma An acute or chronic condition that, in the investigator's opinion, would limit the patient's ability to participate in this study Patients who are currently under a biologic therapy to treat their severe asthma
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Study population<br>Patients completing the inclusión criteria | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood Eosinophil count | The level of eosinophils in the blood will be assessed from this blood sample and reported | There is only one study visit. During that study visit the sample will be collected | 
| Total serum IgE | Total serum IgE will be assessed from this blood sample and reported | There is only one study visit. during that visit the sample will be collected | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
eosinophilic asthma, severe asthma, prevalence, phenotype, atopic phenotype, eosinophilic phenotype